Literature DB >> 19681342

Necrolytic acral erythema: a review of the literature.

Aanand N Geria1, Katherine Z Holcomb, Noah S Scheinfeld.   

Abstract

Necrolytic acral erythema (NAE) has been described as an early cutaneous marker for hepatitis C virus (HCV) infection. It most commonly presents as a well-defined, dusky, erythematous eruption with marked hyperkeratosis and a dark red rim associated with pruritus or burning. Necrolytic acral erythema bears microscopic and clinical resemblance to other necrolytic erythemas, including necrolytic migratory erythema (NME) and several nutrient-deficient syndromes. It is distinct, however, in its predominantly acral distribution and strong association with HCV infection. The pathogenesis is unknown, but a relationship to metabolic alterations has been hypothesized. Optimal therapy appears to be treatment of the underlying HCV infection using a combination of ribavirin and interferon alfa; oral zinc therapy may be an alternative but useful therapy. Cases of NAE without HCV infection suggest that more work needs to be done defining NAE and its relationship to HCV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681342

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  3 in total

1.  Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection.

Authors:  Brian A Raphael; Zachariah L Dorey-Stein; Jason Lott; Valerianna Amorosa; Vincent Lo Re; Carrie Kovarik
Journal:  J Am Acad Dermatol       Date:  2012-02-09       Impact factor: 11.527

2.  Seronegative necrolytic acral erythema: a distinct clinical subset?

Authors:  S Panda; K Lahiri
Journal:  Indian J Dermatol       Date:  2010 Jul-Sep       Impact factor: 1.494

3.  Stevens-Johnson Syndrome in a Patient of Color: A Case Report and an Assessment of Diversity in Medical Education Resources.

Authors:  Darlene Diep; Bineetha Aluri; Alison Crane; Kathleen Miao; Kamilah S Kannan; Robert Goldsteen
Journal:  Cureus       Date:  2022-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.